SUV39H2 is a vulnerability in glioblastoma stem cells enhanced by co-targeting SUV39H1.

IF 2.6 4区医学 Q2 GENETICS & HEREDITY

Epigenomics Pub Date : 2025-10-05 DOI:10.1080/17501911.2025.2568366

Bihui Cao, Qiqi Xie, Chunying Li, Jensen Mast, Bokai Wang, Qinyi Miao, Chafiq Hamdouchi, Timothy A Grese, Jia Shen

{"title":"SUV39H2 is a vulnerability in glioblastoma stem cells enhanced by co-targeting SUV39H1.","authors":"Bihui Cao, Qiqi Xie, Chunying Li, Jensen Mast, Bokai Wang, Qinyi Miao, Chafiq Hamdouchi, Timothy A Grese, Jia Shen","doi":"10.1080/17501911.2025.2568366","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the role of SUV39H2 in glioblastoma (GBM) stem cells (GSCs) and assess whether co-targeting SUV39H2 and SUV39H1 more effectively disrupts GSC maintenance, offering a potential strategy to improve GBM treatment.Methods: Single-cell RNA-seq was used to assess SUV39H2 expression in GSCs. GSC growth and stemness were evaluated using tumorsphere formation assay and extreme limiting dilution assay. Gene expression at the mRNA and protein levels was measured by RT-qPCR and western blot, respectively. Publicly available datasets were analyzed to investigate SUV39H2 expression patterns and its clinical prognostic significance in GBM and glioma.Results: SUV39H2 is overexpressed in GSCs relative to non-stem GBM cells. Its depletion impairs GSC proliferation and stemness. Co-targeting SUV39H2 and SUV39H1 enhances GSC disruption. High SUV39H2 expression correlates with poor glioma prognosis.Conclusion: SUV39H2 is a novel regulator of GSC maintenance. Dual targeting of SUV39H2 and SUV39H1 May offer a potential therapeutic approach for GBM.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1-8"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17501911.2025.2568366","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate the role of SUV39H2 in glioblastoma (GBM) stem cells (GSCs) and assess whether co-targeting SUV39H2 and SUV39H1 more effectively disrupts GSC maintenance, offering a potential strategy to improve GBM treatment.

Methods: Single-cell RNA-seq was used to assess SUV39H2 expression in GSCs. GSC growth and stemness were evaluated using tumorsphere formation assay and extreme limiting dilution assay. Gene expression at the mRNA and protein levels was measured by RT-qPCR and western blot, respectively. Publicly available datasets were analyzed to investigate SUV39H2 expression patterns and its clinical prognostic significance in GBM and glioma.

Results: SUV39H2 is overexpressed in GSCs relative to non-stem GBM cells. Its depletion impairs GSC proliferation and stemness. Co-targeting SUV39H2 and SUV39H1 enhances GSC disruption. High SUV39H2 expression correlates with poor glioma prognosis.

Conclusion: SUV39H2 is a novel regulator of GSC maintenance. Dual targeting of SUV39H2 and SUV39H1 May offer a potential therapeutic approach for GBM.

查看原文本刊更多论文

SUV39H2是胶质母细胞瘤干细胞中的一种易感蛋白，通过共同靶向SUV39H1而增强。

目的：研究SUV39H2在胶质母细胞瘤（GBM）干细胞（GSCs）中的作用，并评估共同靶向SUV39H2和SUV39H1是否更有效地破坏GSC的维持，为改善GBM治疗提供潜在的策略。方法：采用单细胞RNA-seq法检测GSCs中SUV39H2的表达。采用肿瘤球形成试验和极限稀释试验评估GSC生长和干性。RT-qPCR和western blot分别检测mRNA和蛋白水平的基因表达。对公开数据集进行分析，探讨SUV39H2在GBM和胶质瘤中的表达模式及其临床预后意义。结果：相对于非干细胞GBM细胞，SUV39H2在GSCs中过表达。它的缺失损害了GSC的增殖和干性。共同靶向SUV39H2和SUV39H1增强GSC破坏。SUV39H2高表达与胶质瘤预后不良相关。结论：SUV39H2是一种新的GSC维持调节剂。SUV39H2和SUV39H1的双重靶向治疗可能为GBM提供潜在的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epigenomics GENETICS & HEREDITY-

CiteScore

5.80

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community. Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.